Theriva Biologics, Inc. (TOVX) earnings date, results and what the price requires
NYSE · SEC CIK 0000894158 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 11, 2026 | — | — | $-0.07 | Filing |
| Mar 31, 2026 | May 5, 2026 | $300,000 | — | $-0.05 | Filing |
| Dec 31, 2025 | Mar 12, 2026 | — | — | $1.85 | Filing |
| Sep 30, 2025 | Nov 12, 2025 | — | — | $-0.45 | Filing |
| Jun 30, 2025 | Aug 11, 2025 | — | — | $-1.93 | Filing |
| Mar 31, 2025 | May 14, 2025 | — | — | $-1.55 | Filing |
| Dec 31, 2024 | Mar 6, 2025 | — | — | $6.03 | Filing |
| Sep 30, 2024 | Nov 12, 2024 | — | — | $-6.81 | Filing |
What would Theriva Biologics, Inc. have to report for its valuation to change?
At $0.21, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -57.5% a year, to $0.02. On that path the next quarter needs diluted EPS near $-0.19, against $-0.45 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -57.5% | -57.5% |
| EPS needed in final year | $0.02 | $0.02 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. TOVX goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.